Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia

Conclusion Imatinib completely blunts tubular secretion of creatinine, a previously unreported pharmacological property. This inhibition increases serum creatinine independently of any glomerular dysfunction and is fully reversible upon imatinib cessation. Teaser An increase in creatinine has been described in patients treated with imatinib for chronic myeloid leukemia but the underlying mechanism remains unknown. Thorough renal function exploration in 4 patients and populations of matched controls and prospective assessment of creatinine in patients who stopped imatinib or in whom therapy was changed to nilotinib led us to demonstrate that the increase in serum creatinine under imatinib therapy is at least in part due to a functionally reversible inhibition of creatinine tubular secretion.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research